StockDrifts LogoStockDrifts

Lameditech 462510

Company
라메디텍Lameditech
Insiders
0
Buys
0
Total Value
Avg Return
Last Filing
2025-09-19

Lameditech (462510) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Lameditech is dated 2024-06-17; the most recent is 2025-09-19. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-09-19BUY주식매수청구권 행사
장창욱
Changwook Jang
CFO/Vice President32.0K₩7,020-27.5%₩225M ($156K)
2025-06-20BUY기타
강민정
Minjeong Kang
moving2.5K₩8,230-38.1%₩21M ($14K)
2025-03-21BUY주식매수청구권 행사
정봉균
Jeong Bong-gyun
Managing Director55.2K₩7,730-34.1%₩427M ($296K)
2025-03-21BUY주식매수청구권 행사
장창욱
Changwook Jang
CFO/Vice President15.0K₩7,730-34.1%₩116M ($81K)
2025-03-21BUY주식매수청구권 행사
임채승
Lim Chae-seung
Other non-executive directors50.0K₩7,730-34.1%₩387M ($268K)
2024-06-17BUY신규보고
박병철
Park Byeong-cheol
Managing Director176.7K₩24,550-79.3%₩4.3B ($3.0M)
2024-06-17BUY신규보고
임채승
Lim Chae-seung
Other non-executive directors19.3K₩24,550-79.3%₩473M ($328K)
2024-06-17BUY신규보고
최종석
Choi Jong-seok
CEO2.2M₩24,550-79.3%₩53.6B ($37.3M)
2024-06-17BUY신규보고
백광열
Baek Gwang-yeol
moving1.5K₩24,550-79.3%₩37M ($26K)
2024-06-17BUY신규보고
장창욱
Changwook Jang
CFO/Executive Director132.1K₩24,550-79.3%₩3.2B ($2.3M)

Frequently asked questions

Who has been buying Lameditech stock?
0 distinct insiders have filed 0 disclosed insider purchases in Lameditech (462510), most recently on 2025-09-19. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Lameditech have?
Lameditech has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-06-17 to 2025-09-19.
Where does StockDrifts get Lameditech insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Lameditech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.